Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Lilly’s cyramza succeeds in phase 3 urothelial cancer trial Eli Lilly's Cyramza (ramucirumab), in combination with docetaxel, has succeeded in a phase 3 urothelial cancer trial by meeting its primary endpoint of significantly improving progression-free survival (PFS). Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

bluebird unveils topline interim data from Starbeam study of Lenti-D in CALD
bluebird bio has released topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating its investigational gene therapy Lenti-D in under-18 boys with cerebral adrenoleukodystrophy (CALD).
Contract Research & Services > Clinical Trials > News
Roche's emicizumab shows substantial reduction in bleeds in phase III studies
By PBR Staff Writer
Roche’s haemophilia A drug emicizumab has showed a significant effect in the phase III Haven 1 and Haven 2 studies.
Contract Research & Services > Clinical Trials > News

Contract Research

Pamplona to buy US firm Parexel International for $5bn
By PBR Staff Writer
Pamplona Capital Management has agreed to acquire US-based biopharmaceutical services provider Parexel International for around $5bn.
Contract Research & Services > Contract Research > News
AbCellera partners with Sanofi Pasteur to advance influenza vaccine research
AbCellera has partnered with Sanofi Pasteur to advance the research and development of next-generation influenza vaccines.
Contract Research & Services > Contract Research > News

Contract Services

eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents
eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).
Contract Research & Services > Contract Services > News
Immune Pharmaceuticals signs deal to regain global rights for Ceplene
Immune Pharmaceuticals has signed an agreement with Mylan company Meda to repurchase assets relating to Ceplene, including the right to commercialize it in Europe and to register and commercialize in several other countries.
Contract Research & Services > Contract Services > News